




Attorney Docket No. 02332-0020 (49409/284704)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	)	
	)	
Robertson et al.	)	
	)	
Serial No.: 09/857,739	)	Art Unit: 1642
	)	
Filed: June 8, 2001	)	Examiner: Misook Yu
	)	
For: CANCER DETECTION METHODS	)	
AND REAGENTS	)	
	)	

I hereby certify that this correspondence is being deposited with the United States Postal Service on September 19, 2006 via Express Mail, EV333523581US addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

  
Stephen C. MacDonald, Ph.D.

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**


Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the patent publications listed on the attached PTO/SB/08 are submitted for consideration by the Examiner. Copies of the publications are enclosed.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

This Supplemental Information Disclosure Statement is being filed along with a request for continued examination under § 1.114 so no fee is believed due. If a fee is due, the Commissioner is authorized to debit Deposit Account No. 11-0855.

Respectfully submitted,




---

Stephen MacDonald, Ph.D.  
Patent Agent  
Reg. No. L0063

Date: September 19, 2006

KILPATRICK STOCKTON LLP  
Suite 2800, 1100 Peachtree Street  
Atlanta, Georgia 30309-4530  
(404) 815-6500

Attorney Docket No.: 02332-0020 (49409/284704)



Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(use as many sheets as necessary)

Substitute for Form 1449/A/PTO

### Complete if Known

<b>Application Number</b>	<b>09/857,739</b>
<b>Filing Date</b>	<b>June 8, 2001</b>
<b>First Named Inventor</b>	<b>Robertson et al.</b>
<b>Group Art Unit</b>	<b>1642</b>
<b>Examiner Name</b>	<b>Misook Yu, Ph.D.</b>
<b>Attorney Docket Number</b>	<b>02332-0020 (49409/284704)</b>

Sheet	1	of	3
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Kind Code <sup>3</sup> Number <sup>4</sup> (if known)				
	1		WO 96/03502 A2	Ramot University Authority for Applied Research and Industrial Development Ltd.	02-08-1996		
	2		WO 99/58978 A2	University of Nottingham	11-18-1999		
	3		WO 00/26668	The Regents of the University of Michigan	05-11-2000		

**Examiner  
Signature**

Date  
Considered

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Application Number</b>	<b>09/857,739</b>
		<b>Filing Date</b>	<b>June 8, 2001</b>
		<b>First Named Inventor</b>	<b>Robertson et al.</b>
		<b>Group Art Unit</b>	<b>1642</b>
		<b>Examiner Name</b>	<b>Misook Yu, Ph.D.</b>
<b>Sheet</b>	<b>2</b>	<b>of</b>	<b>3</b>
		<b>Attorney Docket Number</b>	<b>02332-0020 (49409/284704)</b>

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	4	APARECIDA et al., "Value of CEA Level Determination in Gallbladder Bile in the Diagnosis of Liver Metastases Secondary to Colorectal Adenocarcinoma", Sao Paulo Medical Journal, 2001, Volume 119, No. 3, pp. 110-113.	
	5	APOSTOLOPOULOS et al., Nature Medicine, 1998, Vol. 4, pp. 315-320.	
	6	BAECHSTROM, et al., "Purification and Characterization of Sialyl-Le - Carrying Mucins of Human Bile; Evidence for the Presence of MUC1 and MUC3 Apoproteins", The Journal of Biological Chemistry, 1994, Volume 269, No. 20, pp. 14430-14437.	
	7	BEATTY, et al., "Biochemical Characterization of the Soluble Form of Tumor Antigen MUC1 Isolated from Sera and Ascites Fluid of Breast and Pancreatic Cancer Patients", Clinical Cancer Research, 2001, Vol. 7, pp. 781-787.	
	8	BEN-MAHREZ et al., British Journal of Cancer, 1988.	
	9	HEHIR et al., Journal of Surgical Oncology, 1993, Vol. 54, pp. 207-210.	
	10	HILL et al., "Nature of Carcinoembryonic Antigen Purified From Malignant Ascitic Fluid of Serous Cystadenocarcinoma of the Ovary", Molecular Immunology, 1981, Vol. 18, No. 7, pp. 647-653.	
	11	KARANIKAS, et al. J Clin Invest 1997 December 1, Vol. 100, No. 11, pp. 2783-2792.	
	12	KURALAY, et al., "Diagnostic Usefulness of Tumour Marker Levels in Pleural Effusions of Malignant and Benign Origin, Clinica Chimica Acta, 2000, Vol. 300, pp. 43-55.	
	13	LAFOND, R.E., et al., "Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians", <i>Autoimmunity</i> , vol. 13, no. 3, 1992, pp. 215-224.	
	14	LAI, et al., "Presence of Serum Anti-P53 Antibodies is Associated with Pleural Effusions and Poor Prognosis in Lung Cancer Patients", Clinical Cancer Research, 1998, Vol. 4, pp. 3025-3030.	
	15	LAWNICZAK, et al., "The Search for Tumor-Associated Proteins in Pleural Effusions by Means of Monoclonal Antibodies and a Dot Blot Assay", Lung, 1992, Vol. 170, pp. 65-74.	
	16	MONTENARH, et al., "P53 Autoantibodies in the Sera, Cyst and Ascitic Fluids of Patients with Ovarian Cancer", International Journal of Oncology, 1998, Vol. 13, pp. 605-610.	
	17	NERY, et al., "Isolation and Partial Characterization of Macromolecular Urinary Aggregates Containing Carcinoembryonic Antigen-Like Activity", Br J. Cancer, 1974, Vol. 29, No. 413,	
	18	NUSTAD et al., "Epitopes on CA 125 from Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies", pp. 303-314.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/857,739
		Filing Date	June 8, 2001
		First Named Inventor	Robertson
		Group Art Unit	1642
		Examiner Name	Misook Yu, Ph.D.
Sheet 3	of 3	Attorney Docket Number	02332-0020 (49409/284704)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>

19	PAVELIC et al., Anticancer Research, 1991, Vol. 11, pp. 1421-1428.	
20	RUSCIANO, "Concomitant Purification of Prostatic Carcinoma Tumor Markers from Human Seminal Fluid Under Nondenaturing Conditions", Clinical Chemistry, 1988, Vol. 34, No. 12, pp. 2528-2532.	
21	SANDRIN et al., Glycoconjugate Journal, 1997, Vol. 14, pp. 97-105.	
22	SCHNEIDER, J. "P53 Protein, EGF Receptor, and Anti-P53 Antibodies in Serum from Patients with Occupationally Derived Lung Cancer", British Journal of Cancer, 1999, Vol. 80, No. 12, pp. 1987-1994.	
23	SHIBATA, et al., "Purification and Characterization of Prostate Specific Antigen from Human Urine", Biochimica et Biophysica Acta, 1997, Vol. 1336, pp. 425-433.	
24	SOKOLOFF, et al., "A Dual-Monoclonal Sandwich Assay for Prostate-Specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine", The Prostate, 2000, Vol. 43, pp. 150-157.	
25	STUBBS, et al., "Faecal Carcinoembryonic Antigen (CEA) in Patients with Large Bowel Cancer", European Journal of Surgical Oncology, 1987, Vol. 13, pp. 433-436.	
26	TONDINI, et al., "Comparison of CA15-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer", Cancer Research, 1988, Vol. 48, No. 14, pp. 4107-4112.	
27	TOTH, et al., "A Carcinoembryonic Antigen (CEA) Binding Protein From Ascites Influences CEA Uptake by Macrophages", 1990, Vol. 171, No. 2, pp. 633-640.	
28	VENEGAS, et al., "Purification and Immunochemical Characterization of Ascitic Fluid Glycoproteins Containing Certain Tumor-Associated and Blood Group Antigen Markers", Glycoconjugate Journal, 1989, Vol. 6, pp. 511-524.	
29	VOLKMANN, M., et al., "Anti-p53 autoantibodies as serological marker in different tumor-entities", Clinical Chemistry, Volume 41, no. S6 part 2, 1995, pp. S221-S222	
30	WOLF, et al., "A Tumour-Associated Antigen from The Pleural Effusion of Patients with Squamous-Cell Carcinoma of Lung", Br. J. Cancer, 1978, Vol. 36, pp. 1046-1052.	
31	YAMAMOTO et al., "L-Myc Overexpression and Detection of Auto-Antibodies Against L-Myc in Both the Serum and Pleural Effusion from a Patient with Non-Small Cell Lung Cancer", Internal Medicine, 1997, Vol. 36, No. 10, pp. 724-727.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.